title: Acute Kidney Injury Associated with Linagliptin.
abstract: Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first case of linagliptin-associated acute kidney injury (AKI) in a patient with preexisting chronic kidney disease (CKD). We hypothesize that AKI was due to renal hypoperfusion from linagliptin-induced natriuresis and intravascular volume contraction in the setting of concomitant lisinopril use, which is known to impair autoregulation and potentiate hypotension-induced AKI. It may be prudent to exert caution and closely monitor kidney function when initiating linagliptin in combination with ACE-inhibitors in CKD patients.
authors.affiliation: Kidney Specialists of Southern Nevada, Las Vegas, NV 89106, USA.
authors.forename: Deepak K
authors.initials: DK
authors.lastname: Nandikanti
authors.affiliation: Nephrology Section, Stratton VA Medical Center, Albany, NY 12208, USA.
authors.forename: Elvira O
authors.initials: EO
authors.lastname: Gosmanova
authors.affiliation: Endocrinology Section, Stratton VA Medical Center, Albany, NY 12208, USA.
authors.forename: Aidar R
authors.initials: AR
authors.lastname: Gosmanov